Champions Oncology Posts Record $59.4M Annual Revenue and Fourth Consecutive Quarter of Positive Adjusted EBITDA
CSBR is trading near its 52-week low of $5.5 (14% above the low).
Summary
Champions Oncology delivered record fiscal 2026 revenue of $59.4 million and its fourth consecutive quarter of positive Adjusted EBITDA. The core business is strengthening, but strategic investments resulted in a GAAP net loss.
Key Events · Earnings and Guidance · CSBR
-
Record Annual Revenue
Fiscal 2026 revenue climbed 4% to a record $59.4 million, as growth in core research services more than offset the absence of a $4.5 million data licensing deal that was recognized in fiscal 2025.
-
Fourth Consecutive Quarter of Positive Adjusted EBITDA
Adjusted EBITDA reached $158,000 for the fourth quarter and $1.6 million for the full year, marking four straight quarters in positive territory and highlighting improved operating leverage.
-
Strategic Investments Pressure GAAP Profitability
A GAAP net loss of $1.2 million for fiscal 2026—compared with net income of $4.7 million in the prior year—reflects deliberate spending on radiopharmaceutical capabilities, the data platform, and commercial expansion.
-
Cash Position and Operating Cash Burn
The company ended the year with $4.9 million in cash and no debt, though net cash used in operating activities totaled $4.5 million, driven largely by working capital timing and growth investments.
Analysis · CSBR · Life Sciences
A record $59.4 million in annual revenue—up 4% year-over-year—and a fourth straight quarter of positive Adjusted EBITDA underscore Champions Oncology's strengthening core. Growth in research services more than compensated for the absence of a prior-year data licensing deal. Strategic investments in radiopharmaceuticals, the data platform, and commercial expansion pushed the company to a GAAP net loss of $1.2 million, yet underlying operational trends continue to improve. With $4.9 million in cash and no debt, the balance sheet is clean, though the $4.5 million in operating cash burn for the year merits close attention. For a small-cap life sciences firm, the results signal disciplined investment for growth alongside careful cost management.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1963 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.14%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CSBR was trading at $6.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.2M. The 52-week trading range was $5.50 to $8.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.